PL3768684T3 - Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl) - Google Patents
Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl)Info
- Publication number
- PL3768684T3 PL3768684T3 PL19711920.9T PL19711920T PL3768684T3 PL 3768684 T3 PL3768684 T3 PL 3768684T3 PL 19711920 T PL19711920 T PL 19711920T PL 3768684 T3 PL3768684 T3 PL 3768684T3
- Authority
- PL
- Poland
- Prior art keywords
- magl
- oxazine
- inhibitors
- monoacylglycerol lipase
- monoacylglycerol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163273 | 2018-03-22 | ||
| CN2019075372 | 2019-02-18 | ||
| PCT/EP2019/057174 WO2019180185A1 (en) | 2018-03-22 | 2019-03-22 | Oxazine monoacylglycerol lipase (magl) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3768684T3 true PL3768684T3 (pl) | 2023-07-10 |
Family
ID=65818027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19711920.9T PL3768684T3 (pl) | 2018-03-22 | 2019-03-22 | Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl) |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210107920A1 (pl) |
| EP (1) | EP3768684B1 (pl) |
| JP (1) | JP7308220B2 (pl) |
| KR (1) | KR20200136425A (pl) |
| CN (1) | CN111936503B (pl) |
| AU (1) | AU2019238381B2 (pl) |
| BR (1) | BR112020014992A2 (pl) |
| CA (1) | CA3089443A1 (pl) |
| CL (1) | CL2020002423A1 (pl) |
| CO (1) | CO2020009567A2 (pl) |
| CR (1) | CR20200416A (pl) |
| DK (1) | DK3768684T3 (pl) |
| ES (1) | ES2942319T3 (pl) |
| FI (1) | FI3768684T3 (pl) |
| HR (1) | HRP20230388T1 (pl) |
| HU (1) | HUE061584T2 (pl) |
| IL (1) | IL276031B2 (pl) |
| LT (1) | LT3768684T (pl) |
| MX (1) | MX2020008894A (pl) |
| PE (1) | PE20201185A1 (pl) |
| PH (1) | PH12020500661A1 (pl) |
| PL (1) | PL3768684T3 (pl) |
| RS (1) | RS64156B1 (pl) |
| SG (1) | SG11202007608UA (pl) |
| SI (1) | SI3768684T1 (pl) |
| TW (1) | TWI818967B (pl) |
| WO (1) | WO2019180185A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| PE20211089A1 (es) * | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| MX2022002311A (es) * | 2019-09-12 | 2022-03-25 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). |
| PE20221450A1 (es) * | 2019-09-23 | 2022-09-21 | Hoffmann La Roche | Compuestos heterociclicos |
| CN114514233A (zh) * | 2019-09-24 | 2022-05-17 | 豪夫迈·罗氏有限公司 | 用于单酰基甘油脂肪酶(magl)的荧光探针 |
| AU2020354414A1 (en) * | 2019-09-24 | 2022-02-17 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (MAGL) inhibitors |
| US20210094972A1 (en) * | 2019-09-24 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| WO2022049134A1 (en) | 2020-09-03 | 2022-03-10 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
| US20240408064A1 (en) * | 2021-10-15 | 2024-12-12 | Genetolead Inc. | Ras inhibitors, compositions and methods of use thereof |
| MX2024008337A (es) | 2021-12-29 | 2024-07-30 | Psy Therapeutics Inc | Inhibicion de la monoacilglicerol lipasa (magl). |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| TW202415651A (zh) | 2022-07-29 | 2024-04-16 | 日商住友製藥股份有限公司 | 含氮飽和雜環衍生物 |
| CN119894887A (zh) * | 2022-09-20 | 2025-04-25 | 豪夫迈·罗氏有限公司 | 用于magl的荧光探针 |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| US7408066B2 (en) | 2005-06-20 | 2008-08-05 | Schering Corproation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
| WO2007098418A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| US9493451B2 (en) | 2011-05-16 | 2016-11-15 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| PL2800565T3 (pl) * | 2012-01-06 | 2020-09-21 | Lundbeck La Jolla Research Center, Inc. | Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| JP2018515612A (ja) | 2015-05-13 | 2018-06-14 | セルビタ スプウカ アクツィーナ | 置換キノキサリン誘導体 |
| CA3199601A1 (en) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| MX379846B (es) | 2015-06-18 | 2025-03-11 | 89Bio Ltd | Derivados de 4-bencil y 4-benzoil piperidina sustituidos. |
| CN105198903B (zh) * | 2015-11-09 | 2016-08-24 | 代先慧 | 一种治疗急性上呼吸道感染的药物组合物 |
| WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
-
2019
- 2019-03-22 WO PCT/EP2019/057174 patent/WO2019180185A1/en not_active Ceased
- 2019-03-22 HU HUE19711920A patent/HUE061584T2/hu unknown
- 2019-03-22 SG SG11202007608UA patent/SG11202007608UA/en unknown
- 2019-03-22 ES ES19711920T patent/ES2942319T3/es active Active
- 2019-03-22 AU AU2019238381A patent/AU2019238381B2/en not_active Ceased
- 2019-03-22 DK DK19711920.9T patent/DK3768684T3/da active
- 2019-03-22 SI SI201930519T patent/SI3768684T1/sl unknown
- 2019-03-22 TW TW108110005A patent/TWI818967B/zh not_active IP Right Cessation
- 2019-03-22 MX MX2020008894A patent/MX2020008894A/es unknown
- 2019-03-22 CN CN201980018255.1A patent/CN111936503B/zh active Active
- 2019-03-22 RS RS20230303A patent/RS64156B1/sr unknown
- 2019-03-22 CR CR20200416A patent/CR20200416A/es unknown
- 2019-03-22 BR BR112020014992-6A patent/BR112020014992A2/pt not_active Application Discontinuation
- 2019-03-22 FI FIEP19711920.9T patent/FI3768684T3/fi active
- 2019-03-22 CA CA3089443A patent/CA3089443A1/en active Pending
- 2019-03-22 KR KR1020207029587A patent/KR20200136425A/ko active Pending
- 2019-03-22 PL PL19711920.9T patent/PL3768684T3/pl unknown
- 2019-03-22 EP EP19711920.9A patent/EP3768684B1/en active Active
- 2019-03-22 LT LTEPPCT/EP2019/057174T patent/LT3768684T/lt unknown
- 2019-03-22 JP JP2020548747A patent/JP7308220B2/ja active Active
- 2019-03-22 HR HRP20230388TT patent/HRP20230388T1/hr unknown
- 2019-03-22 PE PE2020001119A patent/PE20201185A1/es unknown
-
2020
- 2020-07-13 IL IL276031A patent/IL276031B2/en unknown
- 2020-07-31 CO CONC2020/0009567A patent/CO2020009567A2/es unknown
- 2020-09-08 PH PH12020500661A patent/PH12020500661A1/en unknown
- 2020-09-18 US US17/025,155 patent/US20210107920A1/en not_active Abandoned
- 2020-09-21 CL CL2020002423A patent/CL2020002423A1/es unknown
-
2022
- 2022-08-09 US US17/818,459 patent/US20230117324A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276031A (en) | oxazine monoacylglycerol lipase (magl) inhibitors | |
| ZA202006327B (en) | Magl inhibitors | |
| IL279173A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL280762A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL289594A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| IL288936A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| SG11202102281VA (en) | Monoacylglycerol lipase modulators | |
| ZA201905934B (en) | Dual magl and faah inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| ZA202007357B (en) | Lipolytic enzyme variants | |
| PT3768684T (pt) | Inibidores de oxazina da monoacilglicerol lipase (magl) | |
| GB2587631B (en) | An injection lance | |
| PT3894132T (pt) | Um eletrofuso | |
| PL3894133T3 (pl) | Elektrowrzeciono | |
| HK40047049A (en) | Magl inhibitors | |
| MC200226B1 (fr) | Brique de retenue | |
| GB201903621D0 (en) | Wooltop technology | |
| GB201812462D0 (en) | Inhibitors | |
| GB201801832D0 (en) | Furnace | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |